Search research articles
Contact Us
Filters
Showing results (1-10 of 229) with videos related to
Page
of 23
Sort By:
The Journal of Rheumatology. Supplement
|
September 19, 2002
What are the risks of biologic therapy in rheumatoid arthritis? An update on safety
Michael H Weisman
Rheumatic Diseases Clinics of North America
|
October 23, 2012
Inflammatory back pain: the United States perspective
Michael H Weisman
Current Opinion in Rheumatology
|
March 2, 2016
Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis?
Irina Ianculescu, Michael H Weisman
The American Journal of Medicine
|
December 5, 2009
Idiopathic chilblains
Shraddha Prakash, Michael H Weisman
Current Opinion in Rheumatology
|
April 30, 2024
Sacroiliitis in inflammatory bowel disease
Fardina Malik, Michael H Weisman
Clinical and Experimental Rheumatology
|
October 17, 2015
The role of methotrexate in psoriatic arthritis: what is the evidence?
Irina Ianculescu, Michael H Weisman
Rheumatic Diseases Clinics of North America
|
April 7, 2018
US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data
Charles F Dillon, Michael H Weisman
The American Journal of the Medical Sciences
|
July 11, 2013
The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States
John D Reveille, Michael H Weisman
Seminars in Arthritis and Rheumatism
|
March 7, 2003
The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947)
Daniel J Wallace, Michael H Weisman
Current Opinion in Rheumatology
|
May 27, 2020
Spondyloarthritis evolution: what is in your history?
Maedeh Ashrafi, Joerg Ermann, Michael H Weisman
Page
of 23
Search research articles
Search
Showing results (1-10 of 229) with videos related to
Sort By:
Page
of 23
The Journal of Rheumatology. Supplement
|
September 19, 2002
What are the risks of biologic therapy in rheumatoid arthritis? An update on safety
Michael H Weisman
Rheumatic Diseases Clinics of North America
|
October 23, 2012
Inflammatory back pain: the United States perspective
Michael H Weisman
Current Opinion in Rheumatology
|
March 2, 2016
Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis?
Irina Ianculescu, Michael H Weisman
The American Journal of Medicine
|
December 5, 2009
Idiopathic chilblains
Shraddha Prakash, Michael H Weisman
Current Opinion in Rheumatology
|
April 30, 2024
Sacroiliitis in inflammatory bowel disease
Fardina Malik, Michael H Weisman
Clinical and Experimental Rheumatology
|
October 17, 2015
The role of methotrexate in psoriatic arthritis: what is the evidence?
Irina Ianculescu, Michael H Weisman
Rheumatic Diseases Clinics of North America
|
April 7, 2018
US National Health and Nutrition Examination Survey Arthritis Initiatives, Methodologies and Data
Charles F Dillon, Michael H Weisman
The American Journal of the Medical Sciences
|
July 11, 2013
The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United States
John D Reveille, Michael H Weisman
Seminars in Arthritis and Rheumatism
|
March 7, 2003
The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947)
Daniel J Wallace, Michael H Weisman
Current Opinion in Rheumatology
|
May 27, 2020
Spondyloarthritis evolution: what is in your history?
Maedeh Ashrafi, Joerg Ermann, Michael H Weisman
Page
of 23